<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="77474"><DrugName>HS-25</DrugName><DrugNamesKey><Name id="43151261">Haizemaibu</Name><Name id="43151259">Hyzetimibe</Name><Name id="43144502">Saisimei</Name></DrugNamesKey><DrugSynonyms><Name><Value>HS-25</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Haizemaibu</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Saisimei</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Hyzetimibe</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="77474" type="Drug"><TargetEntity id="777284" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="1019688" type="Company"><TargetEntity id="4295865361" type="organizationId">Zhejiang Hisun Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="174" type="ciIndication"><TargetEntity id="10020603" type="MEDDRA"/><TargetEntity id="D006937" type="MeSH"/><TargetEntity id="-1478187279" type="omicsDisease"/><TargetEntity id="969" type="siCondition"/></SourceEntity><SourceEntity id="175" type="ciIndication"><TargetEntity id="10062060" type="MEDDRA"/><TargetEntity id="D006949" type="MeSH"/><TargetEntity id="-1908196798" type="omicsDisease"/><TargetEntity id="971" type="siCondition"/></SourceEntity><SourceEntity id="71" type="Action"><TargetEntity id="693" type="Mechanism">Cholesterol Absorption Inhibitors</TargetEntity></SourceEntity><SourceEntity id="72" type="Action"><TargetEntity id="1052" type="Mechanism">Lipid Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="12755" type="Action"><TargetEntity id="3956" type="Mechanism">Niemann-Pick C1 Protein (NPC1) Inhibitors</TargetEntity><TargetEntity id="3070" type="Mechanism">Niemann-Pick C1-like protein 1 (NPC1L1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-03208" type="ciTarget"><TargetEntity id="1015124298813" type="siTarget">NPC1-like intracellular cholesterol transporter 1</TargetEntity><TargetEntity id="-323783142" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="PR">Pre-registration</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="174">Hypercholesterolemia</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="175">Hyperlipidemia</Indication></IndicationsSecondary><ActionsPrimary><Action id="12755">Niemann-Pick C1-like protein-1 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="71">Antihypercholesterolemic agent</Action><Action id="72">Antihyperlipidemic agent</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C10A</Code><Name>CHOLESTEROL AND TRIGLYCERIDE REDUCTION PREPARATIONS</Name></Ephmra><Ephmra><Code>C10</Code><Name>HYPOLIPIDAEMICS/ANTI-ATHEROMA PREPARATIONS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-20T06:02:58.000Z</LastModificationDate><ChangeDateLast>2019-06-16T00:00:00.000Z</ChangeDateLast><AddedDate>2012-04-24T05:06:44.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1019688" linkType="Company"&gt;Zhejiang Hisun Pharmaceutical&lt;/ulink&gt; is developing an azetidinone analog HS-25 (Hyzetimibe; haizemaibu; Saisimei), a cholesterol absorption inhibitor and Niemann-Pick C1-like protein-1 (NPC1L1) inhibitor, for the potential oral treatment of  primary hypercholesterolemia    [&lt;ulink linkID="1282313" linkType="Reference"&gt;1282313&lt;/ulink&gt;], [&lt;ulink linkID="1344681" linkType="Reference"&gt;1344681&lt;/ulink&gt;], [&lt;ulink linkID="1337701" linkType="Reference"&gt;1337701&lt;/ulink&gt;], [&lt;ulink linkID="1549173" linkType="Reference"&gt;1549173&lt;/ulink&gt;]. In January 2019, an NDA   was accepted in China for  the indication of monotherapy or combination therapy with statins to treatment of primary (heterozygous familial and nonfamilial)  hypercholesterolemia and hypercholesterolemia who are not appropriately controlled with a statin alone [&lt;ulink linkID="2110727" linkType="Reference"&gt;2110727&lt;/ulink&gt;], [&lt;ulink linkID="2131846" linkType="Reference"&gt;2131846&lt;/ulink&gt;]. In May 2014, a phase II trial for   primary hypercholesterolemia was initiated in the US; in December 2014, the trial was completed  [&lt;ulink linkID="1615024" linkType="Reference"&gt;1615024&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The company was also previously developing  HS-25 for the potential treatment of nephrotic hyperlipidemia [&lt;ulink linkID="1282313" linkType="Reference"&gt;1282313&lt;/ulink&gt;], [&lt;ulink linkID="1344681" linkType="Reference"&gt;1344681&lt;/ulink&gt;], [&lt;ulink linkID="1337701" linkType="Reference"&gt;1337701&lt;/ulink&gt;], [&lt;ulink linkID="1549173" linkType="Reference"&gt;1549173&lt;/ulink&gt;]. By December 2013, phase I trials had been completed in China and the US [&lt;ulink linkID="1549173" linkType="Reference"&gt;1549173&lt;/ulink&gt;]. However, no further development was reported since then.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;By June 2018, the company planned to file an NDA in the second half of 2018 [&lt;ulink linkID="2067334" linkType="Reference"&gt;2067334&lt;/ulink&gt;]; in January 2019, an NDA for hypercholesterolemia was accepted in China [&lt;ulink linkID="2110727" linkType="Reference"&gt;2110727&lt;/ulink&gt;]. In March 2019, the application was granted Priority Review in China [&lt;ulink linkID="2129262" linkType="Reference"&gt;2129262&lt;/ulink&gt;], [&lt;ulink linkID="2131846" linkType="Reference"&gt;2131846&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 2012, the company was developing this product as a class 1.1 chemical drug in China [&lt;ulink linkID="1344681" linkType="Reference"&gt;1344681&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In May 2014, a randomized, double-blind, placebo-controlled phase II trial (&lt;ulink linkID="177846" linkType="Protocol"&gt;NCT02087917&lt;/ulink&gt;; HS-25-III) was initiated in the US to evaluate the efficacy and safety of HS-25  in adult patients (n = 376) with primary hypercholesterolemia. In December 2014, the trial was completed  [&lt;ulink linkID="1615024" linkType="Reference"&gt;1615024&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2013,  phase I trials in the US had been completed.  At that time, an application for phase II trials had been approved there [&lt;ulink linkID="1549173" linkType="Reference"&gt;1549173&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2012, an IND had been  approved in the US, presumed to be for phase I trials [&lt;ulink linkID="1282313" linkType="Reference"&gt;1282313&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;By December 2015, a randomized, double-blind, parallel-group, phase III trial (&lt;ulink linkID="327638" linkType="Protocol"&gt;NCT03413462&lt;/ulink&gt;; &lt;ulink linkID="327638" linkType="Protocol"&gt;CTR20150787&lt;/ulink&gt;; HS-25-â…¢-01) had been initiated in China to evaluate the safety and efficacy of HS-25 in patients (expected  n = 360) with primary hypercholesterolemia [&lt;ulink linkID="1720484" linkType="Reference"&gt;1720484&lt;/ulink&gt;]. By January 2018, recruitment was finished. In March 2018, the trial was still ongoing and expected to be completed in April 2018 [&lt;ulink linkID="2044227" linkType="Reference"&gt;2044227&lt;/ulink&gt;]. In September 2018, primary results from  374 patients were reported showing that  the low density lipoprotein-cholesterol (LDL-C) levels decreased -14.6% (FAS) and -16% (FAS). No statistical difference on the adverse reactions were observed  compared to that of placebo group [&lt;ulink linkID="2071381" linkType="Reference"&gt;2071381&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, a randomized, double-blind, phase III trial (&lt;ulink linkID="332435" linkType="Protocol"&gt;NCT03464682&lt;/ulink&gt;; &lt;ulink linkID="332435" linkType="Protocol"&gt;CTR20150351&lt;/ulink&gt;; HS-25-C-01) was planned in China to evaluate the safety and efficacy of HS-25 (10 mg or 20 mg) or in combination with &lt;ulink linkID="2807" linkType="Drug"&gt;atorvastatin&lt;/ulink&gt; (10 mg), in primary hypercholesterolemia patients (expected  n = 720) with low density lipoprotein-cholesterol (LDL-C) after a 12-week period of treatment [&lt;ulink linkID="1674895" linkType="Reference"&gt;1674895&lt;/ulink&gt;]. By June 2018, 629 patients were enrolled. The research had all been completed and entered the final data clearance stage [&lt;ulink linkID="2067334" linkType="Reference"&gt;2067334&lt;/ulink&gt;].  In September 2018, primary results were reported from 255 patients on the basis of atorvastatin(10 mg), LDL-C levels decreased -16.4% (FAS) and -6.8% (FAS), respectively after treatment of HS-25 and atorvastatin, while the adverse reaction rates were 7.9% and 13.6% respectively.The final results would be disclosed after the analysis [&lt;ulink linkID="2071381" linkType="Reference"&gt;2071381&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December  2014, a randomized, double-blind, parallel-group, phase II study (CTR20140610; HS-25-II-01) was initiated in China to evaluate the safety and efficacy of HS-25  in  patients (estimated n = 240) with primary hypercholesterolemia [&lt;ulink linkID="1615025" linkType="Reference"&gt;1615025&lt;/ulink&gt;]. In March 2015, the trial was ongoing [&lt;ulink linkID="1658304" linkType="Reference"&gt;1658304&lt;/ulink&gt;]. In May 2015, the trial was completed [&lt;ulink linkID="1689098" linkType="Reference"&gt;1689098&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2014, an non-randomized, open-label, cross-designed, phase I trial (&lt;ulink linkID="219567" linkType="Protocol"&gt;CTR20140489&lt;/ulink&gt;; HS-25-I-05) was initiated in China to explore the interaction between multiple oral administration HS-25 and &lt;ulink linkID="2807" linkType="Drug"&gt;atorvastatin calcium&lt;/ulink&gt; in Chinese patients (n = 24) with primary hypercholesterolemia. In September 2014, the trial was completed [&lt;ulink linkID="1612199" linkType="Reference"&gt;1612199&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2013, phase I trials had been completed in China  for primary hypercholesterolemia and  nephrotic hyperlipidemia  [&lt;ulink linkID="1549173" linkType="Reference"&gt;1549173&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2013, a randomized, double-blind, positive-control, parallel-group, phase I study (&lt;ulink linkID="177005" linkType="Protocol"&gt;CTR20131499&lt;/ulink&gt;; HS-25-â… -04) was initiated in China to assess safety, tolerability, pharmacokinetic characteristics, and drug effect of 30 mg oral delivered dosage in Chinese hypercholesterolemia subjects (expected n = 40) after two-week oral administration HS-25 tablets. In December 2015, recruitment was ongoing [&lt;ulink linkID="1500618" linkType="Reference"&gt;1500618&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2012, a randomized, double-blind, placebo-controlled, parallel group, phase I study (&lt;ulink linkID="121030" linkType="Protocol"&gt;CTR20130033&lt;/ulink&gt;, HS-25-â… -01, HS-25-â… -02, HS-25-â… -03) was initiated in Chinese healthy volunteers (expected n = 108), to provide dosage and usage data for  a phase II trial  in patients of primary hypercholesterolemia. In December 2015, recruitment was ongoing [&lt;ulink linkID="1401133" linkType="Reference"&gt;1401133&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2012, an IND for a phase I study was submitted;  in  October 2012, approval to conduct a phase I trial was obtained  in China [&lt;ulink linkID="1344681" linkType="Reference"&gt;1344681&lt;/ulink&gt;], [&lt;ulink linkID="1337701" linkType="Reference"&gt;1337701&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By November 2012, preclinical data had shown that  HS-25 was safe and effective. Data also showed that  this product had a similar pharmacological mechanism  to &lt;ulink linkID="11367" linkType="Drug"&gt;ezetimibe&lt;/ulink&gt;, an  NPC1L1 inhibitor and  inhibited cholesterol absorption. However, pharmacokinetics, pharmacodynamics and safety study indicated that HS-25 was more promising than ezetimibe  [&lt;ulink linkID="1344681" linkType="Reference"&gt;1344681&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By June 2014, the project had received funding from the Health and Family Planning Committee of China [&lt;ulink linkID="1612199" linkType="Reference"&gt;1612199&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2012, the project had received funding as part of the "Significant New Drugs" program of the Chinese government's 12th-5 year plan [&lt;ulink linkID="1344681" linkType="Reference"&gt;1344681&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="PA6350149" linkType="Patent"&gt;WO-2011017907&lt;/ulink&gt;, filed by Zhejiang Hisun Pharmaceutical, specifically claims azetidinone compounds (representative structure shown) for the potential treatment of LDL and/or HDL-related disorders.&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2019-01-15T00:00:00.000Z</StatusDate><Source id="2110727" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2014-05-01T00:00:00.000Z</StatusDate><Source id="1615024" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2015-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2015-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2012-04-04T00:00:00.000Z</StatusDate><Source id="1282313" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2012-04-04T00:00:00.000Z</StatusDate><Source id="1282313" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2013-12-31T00:00:00.000Z</StatusDate><Source id="1549173" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2012-12-04T00:00:00.000Z</StatusDate><Source id="1401133" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2014-12-02T00:00:00.000Z</StatusDate><Source id="1689098" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2015-12-08T00:00:00.000Z</StatusDate><Source id="1720484" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2013-12-31T00:00:00.000Z</StatusDate><Source id="1549173" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2013-12-31T00:00:00.000Z</StatusDate><Source id="1549173" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</OwnerCompany><Country id="CN">China</Country><Indication id="174">Hypercholesterolemia</Indication><AwardedIndication>Treatment of primary hypercholesterolemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2019-03-11T00:00:00.000Z</MileStoneDate><Source id="2129262" type="OTHER"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-03208"><Name>Niemann-Pick C1-like protein-1</Name><SwissprotNumbers><Swissprot>Q6T3U3</Swissprot><Swissprot>Q6T3U4</Swissprot><Swissprot>Q9UHC9</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="2790751" number="WO-2014131371" title="Azetidinone compound used for prevention and/or treatment of hepatitis C, and composition of the compound"/><PatentFamily id="3800039" number="WO-2014036956" title="Crystal forms of azetidinone compounds and preparing methods thereof"/><PatentFamily id="4525171" number="WO-2019101150" title="HS-25 tablet and preparation method therefor"/><PatentFamily id="650019" number="WO-2011017907" title="Azetidinone compounds and medical use thereof"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Hisun Pharmaceutical Co Ltd" id="1019688"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fudan University" id="DOL1000375"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>